NCT02718859View on ClinicalTrials.gov

Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

March 1, 2017

Study Completion Date

March 1, 2019

Conditions
Pancreatic Cancer
Interventions
BIOLOGICAL

NK cells

The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd

PROCEDURE

irreversible electroporation (IRE )

The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )

Trial Locations (1)

510000

Central laboratory in Fuda cancer hospital, Guangzhou

All Listed Sponsors
collaborator

Shenzhen Hank Bioengineering Institute

OTHER

lead

Fuda Cancer Hospital, Guangzhou

OTHER

NCT02718859 - Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter